Immix Biopharma receives FDA breakthrough therapy designation for NXC-201
Tweet Send to a Friend
Immix Biopharma Inc. (NASDAQ: IMMX) announced the U.S. Food and Drug Administration granted breakthrough therapy designation to its treatment NXC-201 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


